During the month of September, the Substance Abuse Mental Health Service Administration (SAMHSA) Encourages all alcohol and drug treatment organizations to promote Recovery Month. This increased awareness helps with sharing the understanding of mental and substance use disorders. Recovery Month celebrates the people who recover. The annual theme is Join the Voices for Recovery: Invest in Health, Home, Purpose, and Community.
Summer Sky Treatment Center along with The State of Texas would like first to congratulate all those who are actively living a life of personal recovery. Recovery is an amazing experience and one that all people with alcohol or drug problems should experience. To invest in our personal health by seeking alcohol or drug treatment is the first step in truly investing in health. It all starts with realizing a problem exist and then picking up the phone and reaching out for help. Summer Sky Treatment Center maintains a 24/hour hotline for those looking for alcohol or drug treatment. You can contact them at 1-888-857-8857.
Thousands of men and women have found recovery by attending this alcohol and drug treatment center. They serve that entire State of Texas, Oklahoma, Louisiana, and New Mexico. They are a national alcohol and drug treatment program that offers medical detoxification, Inpatient treatment, residential treatment, and intensive outpatient treatment as well. If you need help for alcohol or drug treatment you can contact Summer Sky Treatment Center at 1-888-857-8857.
NIH-funded multi-site clinical trial suggests that smokers may also benefit.
A new medication that targets part of the brain’s stress system may help reduce alcohol use in people with alcohol use disorder (AUD), according to a new study by researchers at the National Institute on Alcohol Abuse and Alcoholism (NIAAA), part of the National Institutes of Health.
“We’re committed to developing new medications to provide effective therapy to a broader spectrum of people with AUDs.”
—George F. Koob, Ph.D., Director, NIAAA
“Medications have become an important tool for treating alcohol use disorders, but current medications are not effective for all people with AUDs,” noted NIAAA Director George F. Koob, Ph.D. “We’re committed to developing new medications to provide effective therapy to a broader spectrum of people with AUDs.”
As reported online in the journal Neuropsychopharmacology, researchers led by Raye Litten, Ph.D., acting director of the NIAAA Division of Medications Development, conducted a randomized clinical trial of a new compound, called ABT-436, designed to block the effects of vasopressin, a neuropeptide produced in the hypothalamus of the brain.
“Vasopressin helps to regulate the pituitary adrenal axis and other brain circuits involved in emotion,” explained Dr. Litten. “As such, it plays a role in regulating stress, anxiety, and their interaction with AUD.”
Dr. Litten, first author Megan Ryan and their NIAAA colleagues worked with NIAAA’s multi-center Clinical Investigations Group, to recruit 144 alcohol-dependent adult men and women for the 12-week study. During a 28-day baseline period, female participants consumed at least 28 drinks per week, while male participants consumed at least 35 drinks per week. Participants were then randomized to receive either placebo tablets or ones containing the ABT-436 compound. Researchers monitored participants’ alcohol consumption, as well as their mood changes and smoking habits, as these are known to co-vary with alcohol consumption.
Researchers found that participants receiving ABT-436 experienced more days of alcohol abstinence than those receiving the placebo. In particular, participants who reported high levels of stress appeared to respond better to ABT-436, in that both the frequency of their drinking and the number of heavy drinking days they experienced decreased.
“Our findings suggest that potential future studies with drugs targeting vasopressin blockade should focus on populations of people with AUD who also report high levels of stress,” said first author Ryan, a clinical project manager in the NIAAA Division of Medications Development.
Smokers may be another population that could benefit from ABT-436. In addition to its effects on alcohol consumption, study participants receiving the new compound experienced a reduction in smoking. The researchers suspect that ABT-436 might be targeting the same areas in the brain that relate to withdrawal and stress, and, in the process, influencing both tobacco and alcohol use disorders. Additional research is needed to determine if that is the case.
The National Institute on Alcohol Abuse and Alcoholism (NIAAA), part of the National Institutes of Health, is the primary U.S. agency for conducting and supporting research on the causes, consequences, prevention, and treatment of alcohol use disorder, and alcohol problems. NIAAA also disseminates research findings to general, professional, and academic audiences. Additional alcohol research information and publications are available at www.niaaa.nih.gov.
About the National Institutes of Health (NIH): NIH, the nation's medical research agency, includes 27 Institutes and Centers and is a component of the U.S. Department of Health and Human Services. NIH is the primary federal agency conducting and supporting basic, clinical, and translational medical research, and is investigating the causes, treatments, and cures for both common and rare diseases. For more information about NIH and its programs, visit www.nih.gov.
Stephenville, TX - April 1, 2016 – Texas-based alcohol and drug treatment center, Summer Sky Treatment Center—Announces “Spring into Treatment & Recover” Special Rehab Rates.
With over 31-years of providing addiction treatment to over 18,000 families and patients Summer Sky is—taking a new approach to combating the current substance use epidemic. With soaring opiate use disorders and rates of admission to emergency rooms at an all-time high, we are adjusting our treatment rates for those looking for alcohol and drug treatment.
Mr. Scott Kelley President of Summer Sky Treatment Center says this about the adjusted rates “We looked at the current marketplace and noticed that many people were using price as a reason to not go to treatment, so we aim to change this problem by offering an affordable price break for treatment. Our goal is to help more people to access treatment.” With a clinical team that is already, providing cutting edge treatment this price break will add value to a client's treatment.
Summer Sky views it as a privilege to serve customers in Texas and surrounding states. Summer Sky is always striving to improve the lives of those affected by addiction.
Summer Sky Treatment Centeris a nationally recognized alcohol and drug treatment that is accredited by The Joint Commission and licensed by the State of Texas. Summer Sky offers a 30-Day treatment and 90-day treatment for adult males and females.
Contact: Dennis Barkway Admissions Director for more information at 1-888-857-8857 or email him at firstname.lastname@example.org
By: Richard Wolitski, Ph.D., Acting Director, Office of HIV/AIDS and Infectious Disease Policy, U.S. Department of Health and Human Services Cross-posted from the AIDS.gov Blog
The United States is experiencing a growing opioid epidemic, which has made many communities vulnerable to outbreaks of HIV and viral hepatitis among people who inject drugs (PWID). To address this issue, Members of Congress worked together late last year on a broad, bipartisan basis to revise a longstanding ban on the use of federal funds for Syringe Services Programs (SSPs). President Obama signed the bipartisan budget agreement into law, which makes it possible for grantees to use federal funds to support operational components of SSPs under certain circumstances.
To support an implementation of this change in law, the U.S. Department of Health and Human Services (HHS) has released new guidance [PDF 960 KB] for state, local, tribal, and territorial health departments that will allow them to request permission to use federal funds to support SSPs.
A large number of scientific studies have found that SSPs reduce HIV risk. In 2011, the U.S. Surgeon General determined that SSPs are an effective way of reducing HIV transmission among PWID and that there is ample evidence that SSPs promote entry to, and retention in, drug treatment and medical services, without increasing illegal drug use. Many national and community-based organizations worked for years to draw attention to the scientific evidence and to build support for SSPs. The change in the law would not have occurred without their sustained effort.
Requesting Use of Federal Funds
The HHS guidance describes how health departments can request to use federal funds to start or expand SSPs to prevent new HIV and viral hepatitis infections. Federal funds can now be used to support a comprehensive set of services, but they cannot be used to purchase sterile needles or syringes for illegal drug injection.
The guidance states that state, local, tribal, and territorial health departments must consult with the Centers for Disease Control and Prevention (CDC) and provide evidence that their jurisdiction is (1) experiencing, or (2) at risk for significant increases in viral hepatitis infections or an HIV outbreak due to injection drug use.
After receiving a request for determination of need, CDC will have 30 days to notify the requestor whether the evidence is sufficient to demonstrate a need for SSPs. When CDC finds there is enough evidence, state, local, tribal, and territorial health departments and other eligible HHS grant recipients may then apply to their respective federal agencies to direct funds to support approved SSP activities. Each funding agency will be providing specific SSP guidance to its grantees regarding which specific programs may apply and the application process for each institution.
The recent outbreak of HIV and hepatitis C virus (HCV) among persons who were injecting drugs in rural Indiana, and the steep rise nationally in new HCV infections, are powerful reminders that the hard-won gains of the past can be lost if we do not remain vigilant. The opioid epidemic is affecting many communities across the country, and these areas are vulnerable to future outbreaks of HIV and the continued spread of viral hepatitis if we do not work to ensure that robust SSPs and other critical prevention and treatment services are in the place where they are needed. When the local opioid epidemic in Indiana fueled a dramatic increase in the number of new HIV cases, public health officials were able to halt the further spread of the virus by implementing a comprehensive response to identifying and prevent new infections that included SSPs as a key component.
Expanding the reach of SSPs and the services that these programs provide is part of a comprehensive approach to addressing HIV and viral hepatitis among PWID that supports the goals of the updatedNational HIV/AIDS Strategy and the Viral Hepatitis Action Plan to reduce the number of new HIV and viral hepatitis infections. HHS is committed to supporting health departments and all of our partners in the field to conduct SSPs in a way that protects the lives and health of all those at risk for, and living with, HIV and viral hepatitis. In the weeks to come, HHS agencies will be offering additional information and technical assistance to federal grantees that may wish to use federal funds to support operational components of SSPs. Together, our actions will play an important role in preventing new infections among PWID.
Texas-based alcohol and drug rehab have launched an original campaign to increase the war on addiction. Addiction is currently taking the lives of to many people in the United States. Summer Sky, a leading provider of addiction treatment services has " Slam Dunked on Addiction" this campaign seeks to help as many people find addiction treatment as possible. What Summer Sky Treatment Center has done is lower the private pay treatment rate so more people can access drug and alcohol treatment at affordable prices. If you are in need of high-quality addiction treatment and want to save money while you seek help for substance use disorder treatment, then check this addiction program out.
Five Treatment Tips:
1. Affordable treatment does not mean mortgaging the house to find addiction treatment. You should be able to discuss openly with, and addiction treatment program what affordable financial options are available to you, and they should guide you in the right direction to get the needed help you seek. So call and discuss treatment options with the treatment program.
2. Seek out programs that are in-network treatment providers. Most addiction treatment programs are conscious of your personal financial needs, and since the cost of addiction treatment can vary from program to program, in-network treatment centers should help ensure that you get a price break with your insurance company. When you find an in-network treatment provider, you inadvertently save yourself money out of your pocket.
3. No hidden fees when you use in-network treatment providers, this is more convenient than you can imagine. In-network programs can lower the bills that come in after treatment and. No surprises; addictions already produce enough surprises, why not circumvent this issue on the front end of seeking services and go to an in-network provider.
4. Treatment of substance use disorders is already expensive, seeking affordable options for treatment helps you and the individual seeking treatment.
5. While there are many good out of network treatment programs around, please be aware that there are advantages to in-network providers versus out-of-network treatment providers. Do your homework and look for accredited programs.
Texas has some great drug rehabs. The State has seen an expansion in addiction treatment services in the last five years. Most of the expansion has come from the private sector. Many industry veterans have questioned the need for new facilities that have emerged. Much talk has taken place in the area of market research. It seems that some of the facilities have been blinded by the grass is greener on the other side mentality.
The Texas economy is possibly going to reduce it's budget for publicly funded treatment beds this 2011-2012 legislative year. The reality is that 8.4% of people are unemployed. Certainly other States have higher rates, however this is not good for the current treatment industry in Texas. To make things worse health-care benefits have slowly dwindled down or gone away completely with some companies in Texas.
Texas Drug Rehabs are in situations where they must take a look at the actual market and make sound healthy decisions with the opening and expansion of treatment services in the organizations of private and publicly funded drug rehab programs.
The addiction treatment community has wrestled for years fighting addictions and pain. Programs have developed different approaches to treating those with chronic pain issues. It is a difficult and a delicate issue that concerns many in the medical and addiction treatment industry. How to properly detoxify a patient and treat the underline pain that the individual is suffering from can be very tricky. The patient will present for drug treatment with the desire to be removed from pain medications, however the fear from the patient of the pain that will present as soon as medications are removed from the body becomes a barrier for the individual seeking treatment. It is a double edge sword and if not properly done, can create unnecessary pain for the patient.
A powerful new painkiller, which was developed on the basis of the research conducted at Stony Brook University and with no apparent side effects or addictive qualities, may now be only a year or two from the consumer market.
"This offers a major paradigm shift in the control of pain," declares Dr. Simon Halegoua, Professor of Neurobiology & Behavior at Stony Brook who in the 1990s, teamed up with fellow Stony Brook professors Dr. Gail Mandel and Dr. Paul Brehm to identify a novel sodium ion channel involved in the transmission of pain. They predicted that a drug aimed at blocking this channel, PN1/Nav 1.7, would control pain. PN1 (Peripheral Neuron 1), is uniquely expressed in peripheral nerves such as those involved in pain transduction.
When a patient is given an opiate like morphine, pain signals are still transmitted from sensory nerves to the central nervous system. Morphine action throughout the brain reduces and alters pain perception, but it also impairs judgment and results in drug dependence," explains Halegoua, also director of the Center for Nervous System Disorders at Stony Brook University. "With drugs targeting the PN1/Nav1.7 sodium ion channel, the pain signals would not be transmitted, even by the sensory nerves. And since the central nervous system is taken out of the equation, there would be no side effects and no addictive qualities."
The potential for such drugs is enormous -- the reduction or elimination of pain for patients with cancer, arthritis, migraine headaches, muscle pain, pain from burns, and pain from other debilitating diseases.
He notes that drugs in both oral and topical ointment forms, based on the research he conducted in a basement laboratory at Stony Brook with Mandel, a molecular biologist, and Brehm, an electro physiologist, are currently in Phase II clinical trials in England and Canada.
The Research Foundation of the State University of New York is the holder of the various patents originating from the work of the Stony Brook researchers. Icagen Inc., now in partnership with Pfizer, holds the exclusive license to these patents and has announced their own drug has now entered Phase I clinical trials in the U.S.
The above story is reprinted (with editorial adaptations by Sober Sky) from materials provided by Stony Brook University.
addiction news, chronic pain, drug treatment news, Pain, Pain management, Patient, Pfizer, Stanford University, State University of New York, Stony Brook University, Substance dependence, Texas Drug Rehabs
FULTON, MISS. - When Neil Brown got high on bath salts, he took his skinning knife and slit his face and stomach repeatedly. Brown survived, but authorities say others haven't been so lucky after snorting, injecting or smoking powders with such innocuous-sounding names as Ivory Snow, Red Dove and Vanilla Sky.
Law enforcement agents and poison control centers say the bath salts, with their complex chemical names, are an emerging menace in several U.S. states where authorities talk of banning their sale. Some say their effects can be as powerful as those of methamphetamine.
From the Deep South to California, emergency calls are being reported over exposure to the stimulants the powders often contain: mephedrone and methylenedioxypyrovalerone, also known as MDPV.
Sold under such names as Ivory Wave, Bliss, White Lightning and Hurricane Charlie, the chemicals can cause hallucinations, paranoia, a rapid heart rate and suicidal thoughts, authorities say. In addition to bath salts, the chemicals can be found in plant foods that are sold legally at convenience stores and on the Internet. However, they aren't necessarily being used for the purposes on the label.
Mississippi lawmakers this week began considering a proposal to ban the sale of the powders, and a similar measure is being sought in Kentucky. In Louisiana, the bath salts were outlawed by an emergency order after the state's poison center received more than 125 calls in the last three months of 2010 involving exposure to the chemicals.
In Brown's case, he said he had tried every drug from heroin to crack and was so shaken by terrifying hallucinations that he wrote to one Mississippi paper urging people to stay away from the bath salts.
"I couldn't tell you why I did it," Brown said, pointing to his scars. "The psychological effects are still there."
While Brown survived, sheriff's authorities in one Mississippi county say they believe one woman overdosed on bath salts there. In southern Louisiana, the family of a 21-year-old man says he cut his throat and ended his life with a gunshot. Authorities are investigating whether a man charged with capital murder in the December death of a Tippah County, Miss., sheriff's deputy was under the influence of the bath salts.
The stimulants are not regulated by the Drug Enforcement Administration, but are facing federal scrutiny. Law officers say some of the substances are being shipped from Europe, but origins are still unclear.
Gary Boggs, an executive assistant at the DEA, said there is a lengthy process to restrict these types of designer chemicals, including reviewing the abuse data. But it's a process that can take years.
Mark Ryan, director of Louisiana's poison control center, said he thinks state bans on the chemicals can be effective. He said calls about the salts have dropped sharply since Louisiana banned their sale in January.
Ryan said cathinone, the parent substance of the drugs, comes from a plant grown in Africa and is regulated. He said that MDPV and mephedrone are made in a lab and that they are not regulated because they are not marketed for human consumption. The stimulants affect neurotransmitters in the brain, he said.
The drugs cause "intense cravings," he said. "They'll binge on it three or four days before they show up in an ER. Even though it's a horrible trip, they want to do it again and again."
Ryan said at least 25 states have received calls about exposure, including Nevada and California. He said Louisiana leads with the greatest number of cases at 165, or 48 percent of the U.S. total, followed by Florida with at least 38 calls to its poison center.
Rick Gellar, medical director for the California Poison Control System, said the first call about the substances came in Oct. 5, and a handful of calls have followed since. But he warned: "The only way this won't become a problem in California is if federal regulatory agencies get ahead of the curve. This is a brand-new thing."
In the Midwest, the Missouri Poison Center at Cardinal Glennon Children's Medical Center in St. Louis received at least 12 calls in the first two weeks of January about teenagers and young adults abusing such chemicals, said Julie Weber, the center's director. The center received eight calls about the powders all of last year.
Richard Sanders, a general practitioner working in Covington, La., said his son, Dickie, snorted some of the bath salts and endured three days of intermittent delirium. Dickie Sanders cut his throat but missed major arteries. As he continued to have visions, his physician father tried to calm him. But the elder Sanders said that as he slept, his son went into another room and shot himself.
"If you could see the contortions on his face. It just made him crazy," Sanders said. He added that the coroner's office confirmed that the chemicals were detected in his son's blood and urine.
Sanders warns that the bath salts are far more dangerous than some of their names imply.
"I think everybody is taking this extremely lightly. As much as we outlawed it in Louisiana, all these kids cross over to Mississippi and buy whatever they want," he said.
A small packet of the chemicals typically costs as little as $20.
In northern Mississippi's Itawamba County, Sheriff Chris Dickinson said his office has handled about 30 encounters with bath-salts users in the past two months alone. He said the problem grew last year in his rural area after a Mississippi law began restricting the sale of pseudoephedrine, a key ingredient in making methamphetamine.
Dickinson said most of the bath-salts users there have been meth addicts and can be dangerous when using them.
"We had a deputy injured a week ago. They were fighting with a guy who thought they were two devils. That's what makes this drug so dangerous," he said.
But Dickinson said the chemicals are legal, leaving him no choice but to slap users just with a charge of disorderly conduct, a misdemeanor.
Kentucky state lawmaker John Tilley said he's moving to block the drug's sale there, preparing a bill for consideration when his legislature convenes shortly. Angry that the powders can be bought legally, he said: "If my 12-year-old can go in a store and buy it, that concerns me."
ScienceDaily (Dec. 17, 2010) — A little-used medication can help treat alcoholism, an updated review of studies confirms. At any given time, about 5 percent of the population suffers from an addiction to alcohol, often with devastating consequences to work, family, friends and health. Twelve-step programs have been the mainstay for helping alcoholics to quit drinking, but a significant number of people who try these programs do not find them helpful or suffer relapses.
The Cochrane review finds that the medication naltrexone -- brand names are Depade and ReVia -- when combined with counseling or interventions like Alcoholics Anonymous, can help cut the risk of heavy drinking in patients who are dependent on alcohol.
Naltrexone works by blocking the pleasurable feelings, or "high," a person gets from drinking alcohol, thereby reducing motivation to drink. Naltrexone can be taken daily as a pill and is available as a long-acting injection.
The review was published by the Cochrane Collaboration, an international organization that evaluates medical research. Systematic reviews draw evidence-based conclusions about medical practice after considering both the content and quality of existing medical trials on a topic.
"Hundreds of drugs have been tried for relapse prevention [in alcoholism] and basically all others have failed," said Michael Soyka, M.D., senior author of the review. "From a clinical point of view, there are few pharmacologic options for the treatment of alcohol dependence, so it is important to study those options that look promising." Soyka and lead review author Suanne Roesner are associated with the psychiatric hospital at the University of Munich.
Alcohol dependence is different from alcohol abuse or misuse. The symptoms of alcohol dependence include craving for alcohol, an inability to control drinking, the presence of withdrawal symptoms if one tries to quit and tolerance -- the need to increase alcohol amounts to feel the same effect. People who only abuse alcohol and are not dependent on it have no trouble controlling their drinking, once they decide to do so.
Soyka and colleagues examined the results of 50 previously published high-quality studies on naltrexone and alcohol dependence. Overall, the studies enrolled nearly 7,800 patients diagnosed with alcohol dependence. Of these, about 4,200 patients took naltrexone or a similar drug called nalmefene. The rest of the patients took a placebo or had some other type of treatment. Treatment with naltrexone ranged from four weeks to a year, with most patients receiving about 12 weeks of treatment. Most patients also received counseling.
Researchers found that patients who received naltrexone were 17 percent less likely to return to heavy drinking than were patients who received a placebo treatment. "That would mean that naltrexone can be expected to prevent heavy drinking in one out of eight patients who would otherwise have returned to a heavy drinking pattern," Soyka said.
Naltrexone also increased the number of people who were able to stay abstinent by 4 percent.
While at first glance that might not seem like a miracle cure for alcoholism, Soyka said that the effectiveness of naltrexone is on par with medications used for other psychiatric conditions.
"Naltrexone is moderately effective in reducing alcohol intake. It's about as effective as antidepressants in depressive disorders," he said. "From a safety point of view, there are few safety concerns. Nausea is the most frequent side effect."
Carlton Erickson, Ph.D., director of the Addiction Science Research and Education Center at the University of Texas in Austin, says naltrexone can help a person with alcohol dependence move toward the goal of abstinence.
"Anytime you reduce the severity of drinking, the individual is more open to treatment for abstinence," he said. "It's almost like putting them through a series of steps if you can get them to cut down; once they start to cut down they are more likely to become abstinent with continued treatment and continued exposure to 12-step programs." Erickson is not associated with the review or any of its authors.
Despite its possible benefits in treating alcohol dependency, naltrexone is not widely used in the United States or elsewhere, Erickson said. Some addiction specialists fear that the widespread use of naltrexone or other medications will result in patients not receiving the counseling or psychological interventions they need.
There is also a lingering attitude that the treatment of alcohol dependency must rely solely on psychological or spiritual methods.
"People in 12-step programs typically don't believe in medications for the treatment of alcoholism," Erickson said. "Therefore they are unlikely to accept anyone into their 12-step meetings who is on a medication like naltrexone. Secondly, they would not want to accept it for themselves, unless a physician talked them into it as part of their treatment plan."
In addition, most large alcohol treatment centers, with the exception of Hazelden, do not advocate for the use of medications in the management of addiction, he said.
However, Erickson said that naltrexone is FDA-approved only as an adjunct to abstinence-based therapies, like Alcoholics Anonymous. "Naltrexone is not something you give to someone who says 'I want to stop drinking, give me a pill.' Naltrexone is only a helper to that process. The medication itself is not a magic bullet."
The review discloses that two authors received speaker/consultancy/advisory board honoraria from pharmaceutical companies.